Editas Medicine (EDIT) Stock Forecast & Price Target

→ Must-See: Elon’s New Invention is Absolutely Insane (From InvestorPlace) (Ad)

$5.04

-0.03 (-0.59%)

(As of 06/18/2024 ET)

Editas Medicine - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Hold
Based on 10 Analyst Ratings

Consensus Price Target

$12.90
155.95% Upside

High Forecast	$20.00
Average Forecast	$12.90
Low Forecast	$7.00

Type	Current Forecast 6/20/23 to 6/19/24	1 Month Ago 5/21/23 to 5/20/24	3 Months Ago 3/22/23 to 3/21/24	1 Year Ago 6/20/22 to 6/20/23
Consensus Rating	Hold	Moderate Buy	Moderate Buy	Hold
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	4 Buy rating(s)	5 Buy rating(s)	5 Buy rating(s)	6 Buy rating(s)
Hold	6 Hold rating(s)	5 Hold rating(s)	4 Hold rating(s)	7 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	1 Sell rating(s)
Consensus Price Target	$12.90	$13.90	$15.00	$15.93
Forecasted Upside	155.95% Upside	79.21% Upside	60.58% Upside	53.47% Upside

Get Editas Medicine Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for EDIT and its competitors with MarketBeat's FREE daily newsletter.

Ad InvestorPlace

Must-See: Elon’s New Invention is Absolutely Insane

Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street veteran, Eric Fry… This mind-blowing new technology could be bigger than the iPhone.

Click here for the full story…

EDIT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

EDIT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Editas Medicine Stock vs. The Competition

Type	Editas Medicine	Medical Companies	S&P 500
Consensus Rating Score	2.40	2.70	2.50
Consensus Rating	Hold	Moderate Buy	Hold
Predicted Upside	155.95% Upside	1,068.20% Upside	11.31% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
6/18/2024	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Reiterated Rating	Market Perform ➝ Market Perform	$12.00 ➝ $12.00	+138.57%
5/30/2024	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating	L. Bayko Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Target	In-Line ➝ In-Line	$15.00 ➝ $7.00	+36.99%
5/9/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$16.00 ➝ $15.00	+174.22%
5/9/2024	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Equal Weight ➝ Equal Weight	$11.00 ➝ $9.00	+64.84%
5/9/2024	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Underweight ➝ Equal Weight	$7.00	+39.03%
2/27/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral ➝ Neutral	$8.00 ➝ $9.00	+3.09%
Get the Latest News and Ratings for EDIT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Editas Medicine and its competitors with MarketBeat's FREE daily newsletter.
12/12/2023	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$15.00 ➝ $20.00	+102.43%
10/17/2023	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating		Downgrade	Overweight ➝ Neutral
9/28/2023	Stifel Nicolaus Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Hold ➝ Buy	$9.00 ➝ $17.00	+145.66%
8/2/2023	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$22.00 ➝ $19.00	+107.88%
6/12/2023	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating		Upgrade	Market Perform ➝ Outperform	$17.00	+80.47%
2/23/2023	Credit Suisse Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Neutral	$13.00 ➝ $15.00	+52.91%
2/23/2023	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Sector Perform	$14.00 ➝ $10.00	+2.56%
2/23/2023	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target		$36.00 ➝ $30.00	+207.69%
1/23/2023	SVB Leerink Subscribe to MarketBeat All Access for the recommendation accuracy rating	R. Bienkowski Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Target	Market Perform	$6.00 ➝ $7.00	-14.43%
11/18/2022	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Neutral	$18.00 ➝ $15.00	+43.13%
11/18/2022	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$25.00 ➝ $18.00	+63.49%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 06:05 AM ET.

EDIT Forecast - Frequently Asked Questions

What is Editas Medicine's stock forecast and purchase recommendation?: According to the research reports of 10 Wall Street equities research analysts, the average twelve-month stock price forecast for Editas Medicine is $12.90, with a high forecast of $20.00 and a low forecast of $7.00. The consensus rating for Editas Medicine stock is Hold based on the current 6 hold ratings and 4 buy ratings for EDIT. Learn more on EDIT's analyst rating history.
Do Wall Street analysts like Editas Medicine more than its competitors?: Analysts like Editas Medicine less than other "medical" companies. The consensus rating for Editas Medicine is Hold while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how EDIT compares to other companies.
Is Editas Medicine being upgraded by Wall Street analysts?: Over the previous 90 days, Editas Medicine's stock had 1 upgrade by analysts.

Does Editas Medicine's stock price have much upside?: According to analysts, Editas Medicine's stock has a predicted upside of 87.77% based on their 12-month stock forecasts.
What analysts cover Editas Medicine?: Editas Medicine has been rated by research analysts at Barclays, Citigroup, Evercore ISI, Morgan Stanley, and Oppenheimer in the past 90 days.